Bosutinib: A review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

BioDrugs

Volumn 28, Issue 1, 2014, Pages 107-120

  Syed, Yahiya Y ^a   McCormack, Paul L ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CYTOCHROME P450 3A4; DASATINIB; IMATINIB; NILOTINIB;

ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; GENE MUTATION; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANILINE COMPOUNDS; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINOLINES; TREATMENT OUTCOME;

EID: 84895763086     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0082-x     Document Type: Review

References (46)

1. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619-30.
2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science. 1960;132(3438):1497.
3. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii72-7.
4. ®): chronic myelogenous leukaemia, version 1.2014. 2013. http://www.nccn.org/professionals/physician-gls/pdf/cml. pdf. Accessed 5 Dec 2013.
5. Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs. 2007;67(2):299-320.
6. Deininger M, O'Brien S, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract no. 1126]. Blood. 2009;114(22).
7. O'Brien S, Guilhot F, Goldman JM, et al. International randomized study of interferon and STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract no. 186]. Blood. 2008;112(11).
8. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553-61.
9. Michallet M, Tulliez M, Corm S, et al. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin. 2010;26(2):307-17.
10. McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011;71(13):1771-95.
11. Garnock-Jones KP. Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase. Drugs. 2011;71(12):1579-90.
12. Jabbour E, Hochhaus A, Cortes J, et al. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010;24(1):6-12.
13. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119(15):3403-12.
14. Redaelli S, Mologni L, Rostagno R, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012;87(11):E125-8.
15. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib [published erratum appears in Blood 2013; 122 (14): 2524]. Blood. 2011;118(17):4567-76.
16. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314-22.
17. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477-85.
18. US Food and Drug Administration Center for Drug Evaluation and Research. Medical Review(s). 2012. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/ 203341Orig1s000MedR.pdf. Accessed 18 Dec 2013.
19. Pfizer. Bosulif film-coated tablets: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002373/WC500141721.pdf. Accessed 18 Dec 2013.
20. ® (bosutinib): US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/203341s001lbl. pdf. Accessed 18 Dec 2013.
21. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486-92.
22. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63(2):375-81.
23. 2+/calmodulin-dependent protein kinase II gamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res. 2008;68(10):3733-42.
24. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood. 2008;111(4):2329-38.
25. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27(3):469-71.
26. Abbas R, Hug BA, Leister C, et al. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2012;131(3):E304-11.
27. Abbas R, Chalon S, Leister C, et al. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71(1):123-32.
28. Abbas R, Hug BA, Leister C, et al. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol. 2011;51(12):1721-7.
29. Abbas R, Hug BA, Leister C, et al. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69(1):221-7.
30. Abbas R, Leister C, Sonnichsen D. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33(8):589-95.
31. Abbas-Borhan R, Chaudhary I, Hug BA, et al. Mass balance, metabolic disposition, metabolite characterization, and pharmacokinetics of oral 14C-labeled bosutinib in healthy subjects [abstract no. P350]. Drug Metab Rev. 2010;42:228-9.
32. Hsyu PH, Mould D, Abbas R, et al. A population pharmacokinetic (PPK) model of bosutinib (BOS) [abstract no. A195]. Mol Cancer Ther. 2011;10(11 Suppl. 1).
33. Hsyu P-H, Mould DR, Upton RN, et al. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2013;71(1):209-18.
34. US Food and Drug Administration Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). 2012. http://www. accessdata.fda.gov/drugsatfda-docs/nda/2012/203341Orig1s000ClinPharmR.pdf. Accessed 18 Dec 2013.
35. Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2012;36(4):438-42.
36. Cortes JE, Khoury HJ, Lipton JH, et al. Baseline predictors of response to bosutinib in patients with chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib plus dasatinib and/or nilotinib [abstract no. 2793]. Blood. 2012;120(21).
37. Cortes JE, Brummendorf TH, Khoury HJ, et al. Assessment of early cytogenetic response as a predictor of long-term clinical outcomes in a phase 1/2 study of bosutinib in chronic phase CML [abstract no. 2798]. Blood. 2012;120(21).
38. Brümmendorf TH, Cortes JE, Khoury HJ, et al. Bosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 48-month update [abstract no. 2723]. Blood. 2013;122(21).
39. Whiteley J, Reisman A, Kelly V, et al. Health related quality of life of bosutinib in imatinib-resistant or imatinib-intolerant patients with advanced chronic myeloid leukemia [abstract no. 4448]. Blood. 2012;120(21).
40. Whiteley J, Reisman A, Kelly V, et al. Patient perceived impact of diarrhea on health related quality of life in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia treated with bosutinib [abstract no. 4451]. Blood. 2012;120(21).
41. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-84.
42. Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opin Pharmacother. 2013;14(15):2005-10.
43. Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci USA. 2013;110(30):12432-7.
44. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-12.
45. U.S. Food and Drug Administration. FDA drug safety communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. 2013. http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm. Accessed 5 Dec 2013.
46. National Institute for Health and Care Excellence. Bosutinib for previously treated chronic myeloid leukaemia. 2013. http://www.nice.org.uk/ nicemedia/live/14310/65847/65847.pdf. Accessed 5 Dec 2013.